Tianrui Wang

Tianrui Wang


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2020 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
ZNZiyuan Nie
Ziyuan Nie
MZMing-Hui Zhao
Ming-Hui Zhao
BCBao-Qian Cheng
Bao-Qian Cheng
RPRong-Fang Pan
Rong-Fang Pan
TWTianrui Wang
Tianrui Wang
XZXue-Jun Zhang
Xue-Jun Zhang
Background: The roots of Salvia miltiorrhiza are used in traditional Chinese medicine (TCM) and have high medicinal value. Tanshinone IIA (Tan IIA) is the active ingredient of Salvia miltiorrhiza which can inhibit the growth of acute leukemia cell lines in vitro, although the mechanism remains unclear. Methods: CCK-8 assays and BrdU stain were used to evaluate cell proliferation ability. Western blot analysis was used to detect protein expression. miR-497-5p expression level was detected by using qRT-PCR, and Annexin V-FITC/propidium iodide (PI) was used to detect cell apoptosis. Results: Here we reported that Tan IIA could inhibit cell proliferation, induce cell cycle arrest, and promote cell apoptosis in acute myeloid leukemia (AML) cells. Thus, Tan IIA had the anti-cancer activity in AML cell lines, which was likely mediated by up-regulation of miR-497-5p expression. Our data further showed that in AML cells, the same effects were observed with overexpression of miR-497-5p by a miR-497-5p mimic. We demonstrated that Tan IIA could inhibit the expression of AKT3 by up-regulating the expression of miR-497-5p. We subsequently identified that AKT3 was the direct target of miR-497-5p, and that treatment with Tan IIA obviously reversed the effect of treatment with an miR-497-5p inhibitor under harsh conditions. In turn, PCNA expression was increased and cleaved Caspase-3 was suppressed, which contributed to the growth of AML cells. Conclusions: Our results showed that Tan IIA could inhibit cell proliferation in AML cells through miR-497-5p-mediated AKT3 downregulation pathway.

16 July 2025 in Materials Today Bio
Verified
Journal Article
Open access
RZRuizhe Zhao
Ruizhe Zhao
BLBing Liang
Bing Liang
YSYijie Shi
Yijie Shi
JGJianfei Gao
Jianfei Gao
XWXuezhe Wang
Xuezhe Wang
DXDongming Xing
Dongming Xing
Osteoarthritis (OA) is a prevalent joint disorder characterized by progressive cartilage degradation, impaired mesenchymal stem cell (MSC) function, and chronic inflammation, ultimately leading to irreversible structural damage and functional impairment. Despite its high global burden, no regulatory agency has yet approved a disease-modifying therapy for OA, and effective interventions to halt or delay its progression remain a major challenge. Recent research highlights the pivotal role of the immune system in OA pathogenesis, with immunomodulatory biomaterials emerging as a promising strategy to simultaneously regulate inflammatory responses and promote tissue regeneration. These biomaterials, by leveraging their biocompatibility and immunoregulatory properties, offer a transformative alternative to conventional OA therapies, which predominantly focus on symptom management rather than targeting the underlying disease mechanisms. In this review, we comprehensively examine various immunomodulatory biomaterial strategies designed to mitigate OA progression. We first elucidate the immune landscape of OA, detailing the interplay between inflammation and disease pathophysiology. Next, we explore the latest advancements in immunomodulatory biomaterials, including nanoparticles (NPs), hydrogels, and scaffolds, highlighting their potential to reshape OA treatment. Finally, we discuss existing challenges and propose future directions for optimizing biomaterial-based immunotherapies to enhance OA management.

14 November 2025 in Materials Today Bio
Verified
Journal Article
Open access
MYMingyue Yan
Mingyue Yan
KHKehao Hou
Kehao Hou
JZJinpeng Zhao
Jinpeng Zhao
SLShuangshan Li
Shuangshan Li
XWXiaolin Wu
Xiaolin Wu
YZYingze Zhang
Yingze Zhang
The characteristic pathological manifestations of rheumatoid arthritis (RA) include inflammatory cell infiltration, abnormal synoviocyte proliferation, and progressive bone and cartilage destruction. An excessive buildup of reactive oxygen species (ROS) within the joints is a critical factor promoting RA pathological progression. In this study, we innovatively employed a hard template-restricted controlled sintering carbonization strategy to fabricate ultra-small Fe3O4@C nanoparticles with hierarchical structures. The ultra-small Fe3O4@C nanoparticles exhibit multiple natural enzyme-mimic catalytic activity, effectively diminishing intracellular ROS levels in macrophages, while also facilitating the polarization toward the M2 phenotype, and significantly suppresses the production of pro-inflammatory cytokines. Mechanistic investigations reveal that Fe3O4@C significantly suppresses ferroptosis in synoviocytes and chondrocytes through regulation of the SLC7A11/GPX4 signalling pathway, thereby alleviating synovial tissue erosion and promoting type II collagen synthesis. In the collagen-induced arthritis mouse model, Fe3O4@C exhibited remarkable anti-inflammatory and chondroprotective effects, providing an innovative nanozyme therapeutic approach for RA treatment.

22 August 2025 in International Journal of Surgery
Verified
Journal Article
Open access
CLChengsi Li
Chengsi Li
ZYZhenbang Yang
Zhenbang Yang
PYPuxin Yang
Puxin Yang
ZLZhiqiang Li
Zhiqiang Li
TWTianrui Wang
Tianrui Wang
WCWei Chen
Wei Chen
Background: Post-traumatic coagulation and inflammatory activation are associated with various clinical outcomes, and impairments of hematoma formation and inflammatory cell recruitment in the early phases potentially adversely affect bone healing. We aimed to explore and quantify the association between serum platelet-lymphocyte ratio (PLR) levels and postoperative nonunion in patients undergoing extremity fracture Surgery. Methods: This retrospective, multicenter cohort study analyzed data from five tertiary hospitals, including adult patients who underwent surgery for limb fractures between January 2020 and December 2022. The exposure was the post-trauma platelet-to-lymphocyte ratio (PLR), calculated by dividing the platelet count by the lymphocyte count. The outcome of interest was fracture nonunion, defined as the failure of fracture healing for a minimum of 9 months, without evidence of progression toward healing over the preceding 3 months, which was confirmed through a comprehensive review of medical records, telephone follow-ups, and outpatient assessments. Dose–response analysis using restricted cubic spline (RCS) function and multivariate logistic regression were conducted to evaluate the relationship between PLR and nonunion risk. Results: In total, 30 791 patients were included, with an average age of 49.1 ± 16.5 years, and 60.5% were males. Nonunion occurred in 656 patients (2.1%). RCS analysis showed a significant negative non-linear dose–response relationship between PLR and nonunion risk ( P -nonlinearity < 0.001, P -overall < 0.001), and the cutoff value for the risk-protective effect was 145.0. Compared to high PLR levels (≥145.0), lower PLR levels (<145.0) were associated with higher nonunion risk (odds ratio = 1.613; 95% CI, 1.379–1.887; P < 0.001); and this risk effect remained evident after adjustment (adjusted odds ratio = 1.265; 95% CI, 1.057–1.515; P = 0.010). Results are robust across several prespecified sensitivity or exploratory analyses. Subgroup analyses revealed heterogeneity of association according to surgery site and fixation methods ( P values for interaction < 0.050). Conclusion: This study demonstrates that reduced post-trauma PLR levels are associated with an increased risk of nonunion, serving as a potential biomarker for risk stratification and personalized intervention planning during the critical bone healing window.

12 September 2022 in Stem Cells International
Verified
Journal Article
Open access
HZHaibo Zhao
Haibo Zhao
HJHongyuan Jiang
Hongyuan Jiang
HZHaoyun Zhang
Haoyun Zhang
ZSZewen Sun
Zewen Sun
QLQian Lin
Qian Lin
YZYingze Zhang
Yingze Zhang
Adipose-Derived Mesenchymal Stem Cell-Derived Extracellular Vesicles Rescue Tendon Injury in Rat via the miR-19 a/IGFBP3 Axis: Purpose. Adipose-derived mesenchymal stem cells (ADSCs) are increasingly applied in tendon repair. However, the underlying mechanisms of ADSC-derived extracellular vesicles (EVs) in tendon healing are largely unknown. In this study, we investigated the effect of the EVs secreted by ADSCs on the recovery of tendon injuries and its potential mechanism. Materials and Methods. We injected ADSCs into the injured tendon, followed by the evaluation of the tissue morphology, tenocyte proliferation, and oxidative stress. Then, the injured tenocytes were treated with EVs secreted by ADSCs, and oxidative stress and proliferation of tenocytes in vitro were detected. After the overexpression and knockdown of miR-19a and its target protein IGFBP3, the oxidative stress and proliferation of tenocytes in vitro were assessed. Finally, the injured tendon was treated with EVs, and the tissue morphology and proliferation of the injured tendon in vivo were examined. Results. ADSC-derived EVs were found to inhibit oxidative stress and promote proliferation of tenocytes isolated from an injury model of rats. EVs were shown to carry miR-19a which regulated the expression of IGFBP3 through binding to 3UTR of IGFBP3 mRNA. In addition, IGFBP3 promotes oxidative stress and inhibits proliferation of tenocytes. Finally, we found that ADSC-derived EVs promoted tendon wound healing in vivo. Conclusions. Our data suggest that treatment with ADSC-derived EVs ameliorates tendon injury by inhibiting oxidative stress and promoting proliferation in tenocytes. miR-19a carried by ADSC-derived EVs regulates IGFBP3 expression through binding to its 3UTR.

30 December 2025 in Journal of Controlled Release
Verified
Journal Article
Closed access
XHXiaodong Hu
Xiaodong Hu
YCYujiong Chen
Yujiong Chen
JHJian Huang
Jian Huang
SDShuhang Dong
Shuhang Dong
KXKuishuai Xu
Kuishuai Xu
YZYingze Zhang
Yingze Zhang